Novel Rx

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting. COSMOS: Guselkumab in TNF-IR PsA. # OP0230m Coates LC, et al. C-…

Given its multiple domains, there remains much discussion over the best disease activity scoring method in PsA. The proverbial "holy grail" would be a measure that is quick, intuitive, domain…

An analysis of SLE samples from SLE 1760 patients with active disease from RCTs illustrated several known and some new targets for SLE treatment (POS0351). Markers of pathways altered in these…

Combination disease modifying antirheumatic drug (DMARD) therapy may not be only for rheumatoid arthritis; combining disease modifying agents may be the path to better renal…

Here are a few notable presentations from Day 3. BEAT- LUPUS Trial: OP0129 – I would consider this a pilot trial as it only included 52 patients with active SLE, but the gist was that active SLE…

It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it? Oral presentation (6937) discussed that…

The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress,…

In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require…

Check out this compilation of our EULAR 2021 Day 2 broadcasts below. You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com Listen by Clicking below: 1.…

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.